Effect of Shenba Kangliu Liquid on intestinal function, inflammatory index and recurrence after colorectal adenomatous polyp surgery

doi:10.3877/cma.j.issn.2095-2015.2024.05.006

Abstract

Abstract:

Objective

To analyze the effect of Shenba Kangliu Liquid on postoperative intestinal function, inflammatory indexes, and recurrence of colorectal adenomatous polyps.

Methods

A total of 400 patients with colorectal adenomatous polyps admitted to Zhangjiagang Hospital of Traditional Chinese Medicine from January 2021 to September 2022 were selected and randomly divided into an observation group (n=200) and a control group (n=200). Both groups underwent polypectomy under colonoscopy, while the observation group received Shenba Kangliu Liquid treatment for 2 weeks. The recovery time of intestinal function, the restoration of intestinal wall, serum inflammatory indexes and recurrence rate between the two groups were compared.

Results

There were no statistically significant differences in the recovery time of bowel sounds, time to initiate eating, and time to first defecation between the two groups (P>0.05). The thickness of the intestinal wall, the length of the defect, neutrophil count (NEU), neutrophil to lymphocyte ratio (NLR) and systemic immune inflammatory index (SII) decreased in both groups on the 14th day after the operation compared to the 1st day after the operation, while lymphocyte count (LYM) increased. Furthermore, on the 14th day after the operation, the thickness of the intestinal wall, the length of the defect, NEU, NLR, and SII in the observation group were lower than those in the control group (P<0.05), while LYM was higher than that in the control group (P<0.05). The 6-month and 1-year recurrence rates and the total recurrence rate of the observation group were lower than those of the control group (P<0.05).

Conclusion

Shenba Kangliu Liquid can promote the recovery of the intestinal wall and the improvement of inflammatory indexes in patients with colorectal adenomatous polyps without affecting the recovery of intestinal function after the operation. It also has a positive effect on reducing the recurrence rate at 6 months and 1 year after the operation.

Key words: Colorectal adenomatous polyp, Shenba Kangliu Liquid, Intestinal function, Inflammation index, Recurrence

Li Hang, Yaohui Zhang, Wenkai Sun. Effect of Shenba Kangliu Liquid on intestinal function, inflammatory index and recurrence after colorectal adenomatous polyp surgery[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 413-416.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.05.006

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I05/413

Figures/Tables 5

References 20

[1]	Schoen RE, Boardman LA, Cruz-Correa M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma[J]. Clin Cancer Res, 2023, 29(9): 1678-1688.
[2]	Dang DT, Suresh S, Vance RB, et al. Outcomes of cold snare piecemeal EMR for nonampullary small-bowel adenomas larger than 1 cm: a retrospective study[J]. Gastrointest Endosc, 2022, 95(6): 1176-1182.
[3]	齐蕊, 吕书勤. 腺瘤性结直肠息肉术后复发的研究进展[J]. 新疆中医药, 2020, 38(2): 100-103.
[4]	潘迎英, 许纯. 参菝抗瘤液联合化疗治疗晚期胃癌的临床观察[J]. 世界中医药, 2017, 12(2): 362-365.
[5]	Chen YX, Gao QY, Zou TH, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 267-275.
[6]	Yoshida N, Ishikawa H, Otani T, et al. Aspirin-mediated prevention of colorectal adenomas recurrence is affected by blood biochemistry and nutritional intake[J]. Cancer Prev Res, 2022, 15(12): 837-846.
[7]	蔡升, 褚建锋, 周建波, 等. 内镜下切除结直肠腺瘤性息肉的疗效及预后评估[J]. 温州医科大学学报, 2021, 51(3): 237-239, 243.
[8]	Gibbs DC, Barry EL, Fedirko V, et al. Impact of common vitamin D–binding protein isoforms on supplemental vitamin D3 and/or calcium effects on colorectal adenoma recurrence risk: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2023, 9(4): 546-551.
[9]	Pohl H, Anderson J C, Aguilera-Fish A, et al. Recurrence of colorectal neoplastic polyps after incomplete resection[J]. Ann Intern Med, 2021, 174(10): 1377-1384.
[10]	兰琴, 魏玉霞. 影响结肠腺瘤发病的危险因素及预防术后复发研究进展[J]. 中国中西医结合消化杂志, 2021, 29(8): 595-598.
[11]	Ishikawa H, Mutoh M, Sato Y, et al. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy(J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(6): 474-481.
[12]	李盼盼, 贾玉萍, 吴瑞, 等. 基于多参数MRI影像组学模型预测直肠腺瘤癌变的研究[J/OL]. 中华消化病与影像杂志(电子版), 2021, 11(3): 111-116.
[13]	李忠意, 朱传旺, 商竞宇, 等. 民族药三子方防治腺瘤性大肠息肉术后复发的临床观察[J]. 中国中西医结合消化杂志, 2022, 30(7): 500-504.
[14]	Liang J Q, Zeng Y, Kwok G, et al. Novel microbiome signatures for non-invasive diagnosis of adenoma recurrence after colonoscopic polypectomy[J]. Aliment Pharm Ther, 2022, 55(7): 847-855.
[15]	许纯, 刘莲芳, 陶敏贤, 等. 参菝抗瘤液对人胃癌细胞株BGC-823及化疗药物协同作用研究[J]. 湖北中医药大学学报, 2016, 18(6): 10-13.
[16]	杨晓金, 李婷, 蔡波尔, 等. 五个家族性腺瘤性息肉病家系分析[J/OL]. 中华消化病与影像杂志(电子版), 2022, 12(4): 220-223.
[17]	刘莲芳, 许纯, 潘迎英. 基于健脾活血法探讨参菝抗瘤液对人胃癌SGC-7901裸鼠异种移植瘤的抑制作用研究[J]. 福建中医药, 2019, 50(4): 29-32.
[18]	Chang JJ, Chien CH, Chen SW, et al. Long term outcomes of colon polyps with high grade dysplasia following endoscopic resection[J]. BMC Gastroenterol, 2020, 20(1): 1-8.
[19]	Soualy A, Deutsch D, Benallaoua M, et al. Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome(AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial[J]. Trials, 2020, 21(1): 1-8.
[20]	Fiedler D, Hirsch D, El Hajj N, et al. Genome-wide DNA methylation analysis of colorectal adenomas with and without recurrence reveals an association between cytosine-phosphate-guanine methylation and histological subtypes[J]. Genes Chromosomes Cancer, 2019, 58(11): 783-797.

组别	例数	年龄(岁,±s)	性别[例(%)]		病变部位[例(%)]		瘤变分级[例(%)]
组别	例数	年龄(岁,±s)	男	女	结肠	直肠	低级别	高级别
观察组	200	54.69±7.17	117(58.50)	83(41.50)	143(71.50)	57(28.50)	107(53.50)	93(46.50)
对照组	200	55.02±7.26	121(60.50)	79(39.50)	147(73.50)	53(26.50)	112(56.00)	88(44.00)
t/χ²值		0.457	0.166		0.201		0.252
P值		0.648	0.684		0.654		0.615

组别	例数	年龄(岁,±s)	性别[例(%)]		病变部位[例(%)]		瘤变分级[例(%)]
组别	例数	年龄(岁,±s)	男	女	结肠	直肠	低级别	高级别
观察组	200	54.69±7.17	117(58.50)	83(41.50)	143(71.50)	57(28.50)	107(53.50)	93(46.50)
对照组	200	55.02±7.26	121(60.50)	79(39.50)	147(73.50)	53(26.50)	112(56.00)	88(44.00)
t/χ²值		0.457	0.166		0.201		0.252
P值		0.648	0.684		0.654		0.615

组别	例数	肠鸣音恢复	首次进食时间	首次排便时间
观察组	200	15.68±3.51	20.81±4.62	28.71±6.83
对照组	200	15.74±3.66	21.15±4.33	28.59±6.46
t值		0.167	0.759	0.181
P值		0.867	0.448	0.857

组别	例数	肠鸣音恢复	首次进食时间	首次排便时间
观察组	200	15.68±3.51	20.81±4.62	28.71±6.83
对照组	200	15.74±3.66	21.15±4.33	28.59±6.46
t值		0.167	0.759	0.181
P值		0.867	0.448	0.857

组别	例数	肠壁厚度		缺损长度
组别	例数	术后1 d	术后14 d	术后1 d	术后14 d
观察组	200	9.81±1.33	3.11±0.56^*	13.15±2.06	1.92±0.33^*
对照组	200	9.79±1.25	6.03±0.78^*	12.98±1.87	6.71±0.85^*
t值		0.155	43.006	0.864	74.293
P值		0.877	<0.001	0.388	<0.001

Please choose a citation manager

Content to export